 |
|
 |
|
Nurturing cancer survivorship research in the CCOPs
Community Clinical Oncology Programs (CCOPs) are ideally suited to conduct the sort of long-term follow-up with patients that is needed to answer questions about the late effects of treatment, toxicity, and disease.
[more]
|
|
|
|
 |
 |
|
|
|
You, your colleagues, and your cooperative group in the media ...
- The October 1, 2010 Cancer Letter reported that David Alberts, M.D., director of the Arizona Cancer Center and until August vice-chair of SWOG's Gynecologic Committee, received the Association of Community Cancer Centers' 2010 Clinical Research Award at that group's 27th National Oncology Economics Conference. Alberts was honored for his extensive research, leadership, and commitment to individuals with cancer.
- Laurence Baker, D.O., SWOG group chair, was quoted in the November 16 issue of the NCI Cancer Bulletin in a story on the difficulties of moving a promising treatment for Ewing sarcoma into later-phase trials, in spite of its promise. Baker said "The extent of [Roche 1507's] activity in Ewing sarcoma is nearly identical to what was seen with trastuzumab (Herceptin) in breast cancer when it first went into phase II testing."
|
|
|
|
|
|
 |
|
|
|
Bienvenidos! SWOG welcomes INCan
At the Chicago group meeting in October, SWOG welcomed its newest member, the Instituto Nacional de Cancerologia of Mexico, or INCan.
INCan is the Mexican equivalent of the US's National Cancer Institute, and the alliance brings formal Latin American representation into SWOG, expanding the group's scope in the Americas. SWOG also recently added Canada's University of British Columbia as a U10 grant-funded member institution.
SWOG's international initiatives continued with an early November meeting in Costa Rica to plan follow-up studies to the 1,480-patient trial conducted across seven nations in Central and South America that tested alternative antibiotic regimens against infection with Helicobacter pylori bacteria, which is associated with gastric cancer. The hope is that better control of H. pylori will reduce rates of this cancer, one of Latin America's deadliest. The trial reached its accrual goal earlier this year and is now awaiting one-year follow-up testing for many participants.
|
|
|
|
 |
|
